Filtros de búsqueda

Lista de obras de Jonathan M. Brotchie

5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms

artículo científico publicado en 2011

5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat

scientific article published on 01 June 2000

5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.

artículo científico publicado en 2010

A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale

artículo científico

A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.

artículo científico publicado en 2012

A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson’s disease

artículo científico publicado en 2011

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease

artículo científico publicado en 2005

A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats

artículo científico publicado en 2006

A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease

artículo científico publicado en 2005

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease

artículo científico publicado en 2017

Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats

artículo científico publicado en 2006

Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.

artículo científico publicado en 1996

Advances in the delivery of treatments for Parkinson's disease

artículo científico publicado en 2005

Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism

scientific article published on 21 October 2010

Alternating hemiplegia of childhood-related neural and behavioural phenotypes in Na+,K+-ATPase α3 missense mutant mice

artículo científico publicado en 2013

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

artículo científico publicado en 2011

Animal models of α-synucleinopathy for Parkinson disease drug development

artículo científico publicado en 2017

Antidyskinetic actions of amantadine in Parkinson's disease: are benefits maintained in the long term?

artículo científico publicado en 2010

Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.

artículo científico publicado en 2001

Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease

artículo científico publicado en 2000

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors

artículo científico publicado en 2006

Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

artículo científico publicado en 1998

Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors

artículo científico publicado en 2010

CB1 cannabinoid receptor signalling in Parkinson's disease

artículo científico publicado en 2003

Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake.

artículo científico publicado en 2003

Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia

artículo científico publicado en 2011

Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.

artículo científico publicado en 2002

Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.

artículo científico publicado en 2011

Chemical signalling in the globus pallidus in parkinsonism.

artículo científico publicado en 1993

Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146].

artículo científico publicado en 2018

D-[3H]aspartate and [14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents.

artículo científico publicado en 1991

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease

artículo científico publicado en 2017

Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat.

artículo científico publicado en 2012

Dietary resveratrol administration increases MnSOD expression and activity in mouse brain.

artículo científico publicado en 2008

Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus

artículo científico publicado en 2005

Dihydropyridine calcium channel blockers and the progression of parkinsonism

artículo científico publicado en 2012

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

artículo científico publicado en 2008

Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials

artículo científico publicado en 2016

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

artículo científico publicado en 2006

Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease

artículo científico publicado en 2010

Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.

artículo científico publicado en 1999

Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease

artículo científico publicado en 2003

Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats

artículo científico publicado en 2004

Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat.

artículo científico publicado en 2012

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model t

artículo científico publicado en 2010

Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease

artículo científico publicado en 2010

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

artículo científico publicado en 2003

Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.

artículo científico publicado en 1995

Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.

artículo científico publicado en 2008

Gap junction blockers attenuate beta oscillations and improve forelimb function in hemiparkinsonian rats

artículo científico publicado en 2015

Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains

artículo científico publicado en 2011

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

artículo científico publicado en 2006

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

artículo científico publicado en 2010

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease

artículo científico publicado en 2012

Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease

artículo científico publicado en 2003

Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.

artículo científico publicado en 1998

L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

artículo científico publicado en 2012

L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.

artículo científico publicado en 2015

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease

artículo científico publicado en 2012

Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets

artículo científico publicado en 2004

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque

artículo científico publicado en 2004

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

artículo científico publicado en 2004

Levodopa-induced dyskinesia in Parkinson's disease.

artículo científico publicado en 2004

Levodopa-induced dyskinesias

artículo científico publicado en 2007

Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites

artículo científico publicado en 2010

MPTP-induced models of Parkinson's disease in mice and non-human primates

artículo científico publicado en 2005

Management of impulse control disorders in Parkinson's disease: Controversies and future approaches

artículo científico publicado en 2015

Mechanisms compensating for dopamine loss in early Parkinson disease

artículo científico publicado en 2009

Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes.

artículo científico publicado en 1995

Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease

artículo científico publicado en 1996

Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum.

artículo científico publicado en 1995

Monoamine reuptake inhibitors in Parkinson's disease

artículo científico publicado en 2015

Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

artículo científico publicado en 2001

Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.

artículo científico publicado en 2001

Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms.

artículo científico publicado en 1995

Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.

artículo científico publicado en 2010

New approaches to therapy

artículo científico

New insights into the organization of the basal ganglia

artículo científico publicado en 2009

New treatments for movement disorders?

artículo científico publicado en 1996

Non-dopaminergic treatments in development for Parkinson's disease

artículo científico publicado en 2008

Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease

artículo científico publicado en 2004

Nondopaminergic mechanisms in levodopa-induced dyskinesia

artículo científico publicado en 2005

Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat

scientific article published on 01 April 1996

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset

artículo científico publicado en 2003

Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials

artículo científico

Novel pharmacological targets for the treatment of Parkinson's disease

artículo científico publicado en 2006

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

artículo científico publicado en 2008

Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices.

artículo científico publicado en 1997

Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy

artículo científico publicado en 2008

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease

artículo científico publicado en 2006

Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia.

artículo científico publicado en 2006

Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochloride.

artículo científico publicado en 2010

Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.

artículo científico publicado en 2015

Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease

artículo científico publicado en 1996

Presymptomatic compensation in Parkinson's disease is not dopamine-mediated

artículo científico publicado en 2003

Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein

artículo científico publicado en 2011

Pros and cons of a prion-like pathogenesis in Parkinson's disease

artículo científico publicado en 2011

Protection of striatal neurons by joint blockade of D1 and D2 receptor subtypes in an in vitro model of cerebral hypoxia

artículo científico publicado en 2002

RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study

artículo científico publicado en 2012

Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia

artículo científico publicado en 2002

Recent advances in the treatment of L-DOPA-induced dyskinesia.

artículo científico publicado en 2002

Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.

artículo científico publicado en 2008

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

artículo científico publicado en 2010

Reply to "Can STN DBS protect both nigral somata and innervation of the striatum?"

artículo científico publicado en 2017

Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

artículo científico publicado en 2015

Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia

artículo científico publicado en 2004

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit

artículo científico publicado en 2013

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole

artículo científico publicado en 2004

Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.

artículo científico publicado en 2004

Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models

artículo científico publicado en 2014

Selective preservation of MeCP2 in catecholaminergic cells is sufficient to improve the behavioral phenotype of male and female Mecp2-deficient mice.

artículo científico publicado en 2012

Serotonin and Parkinson's disease: On movement, mood, and madness

artículo científico publicado en 2009

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism

artículo científico publicado en 2017

Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus.

artículo científico publicado en 2003

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease

artículo científico publicado en 2002

Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.

artículo científico publicado en 2001

Striatal histone modifications in models of levodopa-induced dyskinesia

artículo científico publicado en 2008

Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.

artículo científico publicado en 2005

Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.

artículo científico publicado en 2017

Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.

artículo científico publicado en 2010

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque

artículo científico publicado en 2013

Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice.

artículo científico publicado en 2008

The Cannabinoid Receptor Agonist WIN 55,212-2 Reduces D2, but Not D1, Dopamine Receptor-Mediated Alleviation of Akinesia in the Reserpine-Treated Rat Model of Parkinson's Disease ⬇️

artículo científico publicado el 1 de noviembre de 1997

The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future

artículo científico publicado en 2010

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

artículo científico publicado en 2004

The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques

artículo científico publicado en 2013

The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

artículo científico publicado en 2015

The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells--The potential of JNX1001 as a therapeutic agent

artículo científico publicado en 2015

The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.

artículo científico publicado en 2012

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease

artículo científico publicado en 2008

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

artículo científico

The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease

artículo científico publicado en 2011

The serotonergic system in Parkinson's disease

artículo científico publicado en 2011

The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates

artículo científico publicado en 2010

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.

artículo científico publicado en 2005

Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury

artículo científico publicado en 2016

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque

artículo científico publicado en 2016

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure

artículo científico publicado en 2006

Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease

artículo científico publicado en 2015

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset

artículo científico publicado en 2014

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque

artículo científico publicado en 2013

Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?

artículo científico publicado en 2018

alpha2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata

artículo científico publicado en 2005

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda